Back
ESC Premium Access

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program

Session: Pharmacology and pharmacotherapy e-posters
Topic: Anticoagulants
Speaker: Doctor L. Dinshaw (Hamburg, DE)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Leon Dinshaw

The University Medical Center Hamburg-Eppendorf, Hamburg (Germany)
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Access
Abstract
Slides
1
Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Access
Abstract
Slides
0
Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Access
Abstract
Slides
0
Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Access
Abstract
Slides
0
Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Access
Abstract
Slides
1
Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor L. Dinshaw, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

27 August 2021

ESC Premium Access

Net clinical benefit of direct oral anticoagulants in very elderly and high bleeding risk patients with atrial fibrillation who are often excluded from oral anticoagulation therapy: a nationwide popul

27 August 2021

ESC Premium Access

2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study

27 August 2021

ESC 365 is supported by

logo Novo Nordisk